Artemether/Lumefantrine and Vivax Malaria

Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01625871

Enrollment

Registered

2012-06-22

Start date

2011-09-30

Completion date

2012-09-30

Last updated

2013-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vivax Malaria

Keywords

malaria, vivax, artemether/lumefantrine, Sudan

Brief summary

The cure rate of artemether/lumefantrine in the treatment of vivax malaria.

Interventions

DRUGtablets artemether/lumefantrine

six doses of oral tablets of artemether/lumefantrine

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

5 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with vivax malaria

Exclusion criteria

* severe malaria * pregnancy

Design outcomes

Primary

Measure	Time frame	Description
The cure rate	28 days	The proportion of the cure patients

Secondary

Measure	Time frame	Description
Fever clearance time	28 days	The time for fever clearance
Parasite clearance time	28 days	The time for the parasite to clear

Countries

Sudan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026